Qlucore Announces 3 Year License from Actelion
News Jul 14, 2015
Qlucore has announced a three year license contract with Actelion, one of Europe’s leading biopharmaceutical companies.
Actelion is a leader in the science and medicine of pulmonary arterial hypertension (PAH), and its understanding of the complex pathways and molecular mechanisms of this disease has enabled the development of tailored medicines that can make a real difference to patient outcomes. With over 15 years of experience, Actelion’s Drug Discovery group, based in Allschwil, Switzerland combines technology with human expertise and teamwork.
Scientists use an inquisitive drug hunting approach to discover and develop novel medicines to improve patients' lives. Actelion has over 100 medicinal and process chemists creating low molecular weight compounds which go through a cyclical drug discovery process for optimization. These innovative compounds are then characterized by molecular biologists and biochemists in relation to the chosen molecular drug targets.
Actelion has been using Qlucore Omics Explorer for exploration and analysis of large data sets, mainly within Translation Science, since 2011. One of the most pressing challenges facing scientists today is what’s known as “big data” - complex datasets that have grown so large that they become nearly impossible to analyze using traditional tools.
“We are delighted that Actelion is making this long-term commitment to Qlucore with the multi-year license.” commented Carl-Johan Ivarsson, President of Qlucore “This shows the confidence that Actelion has in our product and is an endorsement of not only of our software but the working relationship between our two companies.”
For scientists and researchers the benefits of working with larger and larger data sets allows them to spot trends and ultimately help in the fight against human disease. However, faced with such large volumes of data, it is often very difficult - if not impossible - for scientists to derive any real biological meaning from their findings with the naked eye alone and researchers face big problems and delays trying to analyze the sheer quantity of data.
Qlucore Omics Explorer features the latest data visualization techniques and presentation technologies which is making it much easier for researchers to examine enormous quantities of data, to test different hypothesis much more quickly, and to explore alternative scenarios within seconds, all without having to rely exclusively on the help of specialist bioinformaticians and biostatisticians.
Biologists within Actelion’s research organizations have become more active in data analysis and exploration by using Qlucore Omics Explorer. Actelion plans to increase its use of Qlucore’s software, extending to more research teams by placing this 3 years license order.
Biometric System Measures Brainwaves, Creates Brain PasswordNews
The “brain password” could have implications in banking, law enforcement, airport security and other areas.READ MORE
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
RedSeed Ventures Financially Supports the Innovative SME with 2.5 Million EuroNews
New partners are joining Pasquale Fedele, the inventor of BrainControl, who gained a total of 2.5 million Euro in a round of funding led by the Italian based investment firm RedSeed Ventures.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018